The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000488.4(SERPINC1):c.1154-53G>A

CA10960823

1279654 (ClinVar)

Gene: SERPINC1
Condition: antithrombin III deficiency
Inheritance Mode: Autosomal dominant inheritance
UUID: fc345533-efb9-4fd1-9c6f-446956feb6cd
Approved on: 2023-07-25
Published on: 2023-09-29

HGVS expressions

NM_000488.4:c.1154-53G>A
NM_000488.4(SERPINC1):c.1154-53G>A
NC_000001.11:g.173907567C>T
CM000663.2:g.173907567C>T
NC_000001.10:g.173876705C>T
CM000663.1:g.173876705C>T
NC_000001.9:g.172143328C>T
NG_012462.1:g.14812G>A
ENST00000367698.4:c.1154-53G>A
ENST00000367698.3:c.1154-53G>A
ENST00000617423.4:c.560-74G>A
NM_000488.3:c.1154-53G>A
NM_001365052.1:c.1010-53G>A
NM_001365052.2:c.1010-53G>A
NM_001386302.1:c.1277-53G>A
NM_001386303.1:c.1235-53G>A
NM_001386304.1:c.1133-53G>A
NM_001386305.1:c.1097-53G>A
NM_001386306.1:c.938-53G>A
More

Benign

Met criteria codes 2
BA1 BS2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Thrombosis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for SERPINC1 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Thrombosis VCEP
The NM_000488.4:c.1154-53G>A variant is reported at a popmax FAF of 0.3028 and the highest MAF of 0.3263 (32%; 507/1554 alleles with 81 homozygotes) in the East Asian population in gnomAD v2.1.1, meeting criteria for BA1 (MAF >0.002). The variant is reported in 8 individuals with normal antithrombin levels. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: BA1, BS2.
Met criteria codes
BA1
The variant is reported at a popmax FAF of 0.3028 and the highest MAF of 0.3263 (32%; 507/1554 alleles with 81 homozygotes) in the East Asian population in gnomAD v2.1.1.
BS2
The variant is reported in 11 individuals from internal laboratory data. Eight have antithrombin levels of ≥0.8 IU/mL. Two report VTE but have normal (0.8 IU/mL) or near normal (0.78 IU/mL) antithrombin levels. BS2 is applied based on >2 heterozygotes with normal antithrombin levels.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.